Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion
Clinical trial NCT05466149 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05466149
- Sponsor
- Allist Pharmaceuticals, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-27
- Primary completion
- 2025-06-27
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.